Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

NEK1 kinase domain structure and its dynamic protein interactome after exposure to Cisplatin

Full text
Author(s):
Show less -
Melo-Hanchuk, Talita D. ; Slepicka, Priscila Ferreira ; Meirelles, Gabriela Vaz ; Basei, Fernanda Luisa ; Lovato, Diogo Ventura ; Granato, Daniela Campos ; Pauletti, Bianca Alves ; Domingues, Romenia Ramos ; Paes Leme, Adriana Franco ; Pelegrini, Alessandra Luiza ; Lenz, Guido ; Knapp, Stefan ; Elkins, Jonathan M. ; Kobarg, Jorg
Total Authors: 14
Document type: Journal article
Source: SCIENTIFIC REPORTS; v. 7, JUL 14 2017.
Web of Science Citations: 4
Abstract

NEK family kinases are serine/threonine kinases that have been functionally implicated in the regulation of the disjunction of the centrosome, the assembly of the mitotic spindle, the function of the primary cilium and the DNA damage response. NEK1 shows pleiotropic functions and has been found to be mutated in cancer cells, ciliopathies such as the polycystic kidney disease, as well as in the genetic diseases short-rib thoracic dysplasia, Mohr-syndrome and amyotrophic lateral sclerosis. NEK1 is essential for the ionizing radiation DNA damage response and priming of the ATR kinase and of Rad54 through phosphorylation. Here we report on the structure of the kinase domain of human NEK1 in its apo-and ATP-mimetic inhibitor bound forms. The inhibitor bound structure may allow the design of NEK specific chemo-sensitizing agents to act in conjunction with chemo-or radiation therapy of cancer cells. Furthermore, we characterized the dynamic protein interactome of NEK1 after DNA damage challenge with cisplatin. Our data suggest that NEK1 and its interaction partners trigger the DNA damage pathways responsible for correcting DNA crosslinks. (AU)

FAPESP's process: 10/51730-0 - Functional and structural studies of protein kinases involved in cancer and neglected diseases: towards the development of new inhibitors
Grantee:Jörg Kobarg
Support Opportunities: Regular Research Grants